MAM
CRNX icon

Meeder Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Meeder Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.43K Buy
177
+128
+261% +$5.72K ﹤0.01% 785
2025
Q4 		$2.28K Sell
49
-69
-58% -$3.07K ﹤0.01% 861
2025
Q3 		$4.92K Buy
118
+20
+20% +$639 ﹤0.01% 678
2025
Q2 		$2.82K Buy
98
+34
+53% +$1.05K ﹤0.01% 785
2025
Q1 		$2.15K Sell
64
-17
-21% -$635 ﹤0.01% 863
2024
Q4 		$4.14K Buy
81
+5
+7% +$280 ﹤0.01% 853
2024
Q3 		$3.88K Buy
+76
New +$3.92K ﹤0.01% 782
2021
Q4 		– Sell
-1,988
Closed -$42K – 1420
2021
Q3 		$42K Buy
+1,988
New +$41.6K ﹤0.01% 1143

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Meeder Asset Management's CRNX Position: Q1 2026 in Review

Meeder Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 261% in Q1 2026, buying an estimated $5.72K and bringing the position to 177 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #785.

Meeder Asset Management first reported a position in CRNX in Q3 2021 and has held it in 8 quarters since. The position peaked at $42K in Q3 2021. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Meeder Asset Management held 177 shares of Crinetics Pharmaceuticals worth $6.43K as of Q1 2026.
  • Meeder Asset Management bought 128 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $5.72K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #785 holding.
  • Meeder Asset Management first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
  • Meeder Asset Management's Crinetics Pharmaceuticals position peaked at $42K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.